Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian Heinzmann

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Current Opinion in Supportive and Palliative Care|April 2, 2011
New molecules for the treatment of painSebastian Heinzmann, Stephen B McMahon
ACS Applied Materials & Interfaces|April 22, 2026
Charge Injection and Interfiber Electrical Conduction in Cable BacteriaCosimo Tommasi, Anastasia Gerzhik, Sebastian Heinzmann, et al.
Plos One|June 15, 2007
High-threshold mechanosensitive ion channels blocked by a novel conopeptide mediate pressure-evoked painLiam J Drew, Francois Rugiero, Paolo Cesare, et al.
JTO Clinical and Research Reports|June 6, 2022
Long-Term Efficacy and Safety of Entrectinib in <i>ROS1</i> Fusion-Positive NSCLCAlexander Drilon, Chao-Hua Chiu, Yun Fan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2022
Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid TumorsGeorge D Demetri, Filippo De Braud, Alexander Drilon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2022
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid TumorsGeorge D Demetri, Filippo De Braud, Alexander Drilon, et al.
Thyroid : Official Journal of the American Thyroid Association|November 27, 2023
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW StudyVivek Subbiah, Mimi I Hu, Aaron S Mansfield, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Current Opinion in Supportive and Palliative Care|April 2, 2011
New molecules for the treatment of painSebastian Heinzmann, Stephen B McMahon
ACS Applied Materials & Interfaces|April 22, 2026
Charge Injection and Interfiber Electrical Conduction in Cable BacteriaCosimo Tommasi, Anastasia Gerzhik, Sebastian Heinzmann, et al.
Plos One|June 15, 2007
High-threshold mechanosensitive ion channels blocked by a novel conopeptide mediate pressure-evoked painLiam J Drew, Francois Rugiero, Paolo Cesare, et al.
JTO Clinical and Research Reports|June 6, 2022
Long-Term Efficacy and Safety of Entrectinib in <i>ROS1</i> Fusion-Positive NSCLCAlexander Drilon, Chao-Hua Chiu, Yun Fan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2022
Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid TumorsGeorge D Demetri, Filippo De Braud, Alexander Drilon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2022
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid TumorsGeorge D Demetri, Filippo De Braud, Alexander Drilon, et al.
Thyroid : Official Journal of the American Thyroid Association|November 27, 2023
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW StudyVivek Subbiah, Mimi I Hu, Aaron S Mansfield, et al.
Pageof 1